Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 192
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Natural history/Epidemiology, Treatment
Active
18 and over
Pharmaceutical / Industry
CR012361
NCT00440479
2.
VALEO: A Post Authorization Survey, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Natural history/Epidemiology, Treatment
Active
18 and over
Pharmaceutical / Industry
CR003469
NCT00440765
3.
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Other
TaCyDexVMP7
NCT00652041
Last Modified:
9/10/2008
 
First Published:
4/23/2005
4.
Phase III Randomized Study of Melphalan and Prednisone With Versus Without Bortezomib in Older Patients With Newly Diagnosed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
65 and over
NCI, Pharmaceutical / Industry
UCLA-0409110-01
JJPRD-26866138-MMY-3002, NCT00111319
5.
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
EudraCT: 2005-001628-35
EBMT-CLWP: 42206611, NCT00256776
6.
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
BRD 04/11-J
NCT00200681
7.
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
61 to 75
Pharmaceutical / Industry
CR006127
NCT00416208
8.
Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma Age < 60 Years.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
0 to 60
Pharmaceutical / Industry
CR006124
NCT00416273
9.
Efficacy of Bortezomib Consolidation After High-Dose Melphalan With Stem Cell Support in Myeloma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
NMSG 15/05
EudraCT No: 2005-002756-18, NCT00417911
10.
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
66 and over
Other
2005-001111-21
NCT00443235
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute